Showing 331-340 of 1560 results for "".
Long-Term Survival Data in High-Risk NSCLC: Insights from Real-World Practice
https://reachmd.com/programs/project-oncology/long-term-survival-data-in-high-risk-nsclc-insights-from-real-world-practice/35995/While clinical trials have demonstrated the value of immunotherapy in advanced non-small cell lung cancer (NSCLC), real-world outcomes often reflect a more complex picture. That’s why a retrospective analysis of more than 17,000 patients examined 5-year survival and progression-free survival in patiEvaluating Flu Vaccine Effectiveness in Pediatric Populations
https://reachmd.com/programs/vaccination/evaluating-flu-vaccine-effectiveness-in-pediatric-populations/36267/Recent research highlights the comparative effectiveness of cell-based versus egg-based influenza vaccines in pediatric populations. This data could help guide pediatric immunization, alongside strategies like comprehensive communication with parents and whole-family vaccine efforts. Joining Dr. BriThe Future of Performance Enhancing Drugs and Testing
https://reachmd.com/programs/focus-on-sports-medicine/the-future-of-performance-enhancing-drugs-and-testing/3001/Looking beyond steroids in professional sports; what are the major drugs, how do they work, and who is using them? Looking at the red blood cell-boosting EPO, HGH, and the future of testing for performance enhancing drugs in sports is your host, Dr. Gary Kohn. Joining him is one of the world's premiCAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
https://reachmd.com/programs/project-oncology/car-t-in-marginal-zone-lymphoma-insights-from-the-transcend-fl-study/35455/CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall response rate and sustOptimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
https://reachmd.com/programs/project-oncology/optimizing-nivolumab-in-nsclc-implications-for-cost-access-and-outcomes/32997/Emerging evidence suggests that combining low-dose nivolumab and chemotherapy in the neoadjuvant setting may retain immunologic efficacy while drastically lowering cost and toxicity for non-small cell lung cancer (NSCLC) patients. Additionally, this approach could help optimize trial design with dosReducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
https://reachmd.com/programs/neurofrontiers/reducing-cortical-lesions-in-ms-with-ocrelizumab-results-from-the-oratori-study/26763/Does the B-cell therapy ocrelizumab have the potential to slow down cortical lesions or even stop them in multiple sclerosis (MS)? That’s the exact question the ORATORI study sought to answer, and based on the findings, not only did ocrelizumab reduce new and enlarging cortical lesions by 75 percentBest Practices for Existing Epidermal Growth Factor Receptor (EGFR) Inhibitor Agents
https://reachmd.com/programs/global-oncology-academy/best-practices-for-existing-epidermal-growth-factor-receptor-egfr-inhibitor-agents/9541/The management of metastatic colorectal cancer (mCRC) and metastatic and recurrent loco-regional squamous cell cancer of the head and neck (SCCHN) continues to evolve, not only as new agents reach the clinic but also new understandings of how best to utilize existing agents to optimize clinical outcA New Paradigm for the Treatment of Type 2 Diabetes
https://reachmd.com/programs/diabetes-discourse/a-new-paradigm-for-the-treatment-of-type-2-diabetes/4803/Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the wAssessing Nivolumab + Ipilimumab in mNSCLC: 6-Year Outcomes from CheckMate 9LA
https://reachmd.com/programs/project-oncology/assessing-nivolumab-ipilimumab-in-mnsclc-6-year-outcomes-from-checkmate-9la/35996/The CheckMate 9LA trial evaluated nivolumab plus ipilimumab with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (mNSCLC) in patients with low PD-L1 expression. The final, 6-year results show durable survival benefits, with nearly threefold higher long-term survivalOptimizing NSCLC Care: Advances in Lung Biopsy and Biomarker Testing
https://reachmd.com/programs/deep-breaths-updates-chest/program-name/35980/Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role o